1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

11. R. Brentjens, E. Santos, R. Yeh, K. La Perle, R. Toledo-Crow, Y. Nikhamin, B. Punzalan, D. Entenberg, I.Aranda, B. Punzalan, S. Larson, M. Sadelain. Sensitive In Vivo Detection of Primary T Cells ExpressingMembrane-Anchored Gaussia Luciferase for the Study of Adoptive T Cell Immunotherapy in Murine Modelsof Malignancy [Abstract]. Blood, 2006; 108: 3685a.12. R Brentjens; E Santos; Y Nikhamin; R Yeh; M Matsushita; K La Perle; A Quintas-Cardama; S Larson; MSadelain Successful eradication of systemic acute lymphoblastic leukemia xenografts by genetically targeted Tcells is limited by in vivo T cell co-stimulation and persistence. [Abstract]. Keystone Symposia 2007, PotentNew Anti-tumor Therapies. Poster #123.13. I Riviere, D Hollyman, J Stefanski, M Przybylowski, V Capacio, O Borquez-Ojeda, S Bartido, J Hosey, MSadelain, R Brentjens. CD19-targeted CLL patient T cells expanded with beads eradicate systemic B celltumors in vivo [Abstract]. Keystone Symposia 2007, Potent New Anti-tumor Therapies. Poster #305.14. J Lee, Y Nikhamin, R Brentjens. Functional Characterization of Genetically Modified Tumor-TargetingRegulatory T Cells [Abstract]. World Immune Regulation Meeting 2007. Poster #241.15. D Hollyman, J Stefanski, M Przybylowski, S Bartido, O Borquez-Ojeda, V Capacio, K Smith, J Hosey, CTaylor, R Brentjens, M Sadelain, I Reviere. Validation of a large scale semi-closed system for themanufacture of autologous T cells genetically targeted to the B cell specific antigen CD19 for a phase I trial inpatients with chronic lymphocytic leukemia [Abstract] Mol Ther. 2007;15:S165.16. R Brentjens, E Santos, R Yeh, Y Nikhamin, K LaPerle, S Larson, M Sadelain. Utilization of a novel luciferaseconstruct to demonstrate trafficking of genetically targeted CD19 specific T cells to systemic human acutelymphoblastic leukemia in a mouse [Abstract]. Mol Ther. 2007;15:S22417. R. Brentjens, I. Rieviere, D. Hollyman, J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda, C.Taylor, J.Hosey, M. Heaney, M. Weiss, M. Sadelain. A phase I trial for the treatment of purine analoguerefractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specificantigen CD19 [Abstract]. 12 th International Workshop on CLL. Leuk. Lymph. 2007; 48(Supplement 1): S173.18. James Lee, Yan Nikhamin, Gavin Imperato, Adam Cohen, Michel Sadelain, and Renier J. Brentjens. Efficacyand Long Term Survival of Genetically Modified T cells Targeting CD19 in a Syngeneic Immune CompetentTransgenic Murine Tumor Model is Dependent on Prior Lymphodepleting Chemotherapy. Blood 2007; 10919. RJ Brentjens, D Hollyman, M Weiss, J Stefanski, M Przybylowski, S Bartido, O Borquez-Ojeda, C Taylor, JHosey, M Heaney, M Sadelain, I Riviere. A Phase I Trial for the Treatment of Chemo-Refractory ChronicLymphocytic Leukemia with CD19-Targeted Autologous T cells. [Abstract: Oral Presentation] Mol. Ther.2008;16:S1 ( Oral Presentation #38)20. J Lee, M Sadelain, RJ Brentjens. Tumor-targeted human CD4+ CD25 hi regulatory T cells effectively inhibit Tcell mediated rejection of CD19+ tumors in an in vivo xenotransplant tumor model [Abstract] Blood 2008; 112:poster 3901.21. J Lee, M Sadelain, RJ Brentjens. Tumor Targeted T cells modified to express IL-12 overcome inhibitionmediated by the hostile tumor microenvironment [Abstract]. Keystone symposia 2009, Mobilizing CellularImmunity for Cancer Therapy (A3). Snowbird UT, 1/11-1/16/09.22. J Lee, M Sadelain, RJ Brentjens. Tumor-targeted T cells modified to expressIL-12 overcome inhibitionmediated by the hostile tumor microenvironment [Abstract] Mol Ther 2009; 17:S8919